Tag: duocort
Nov 07, 2011 07:00 EST The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren® (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
Oct 27, 2011 07:33 EDT DuoCort AB announces it has signed a definitive agreement to sell DuoCort Pharma AB and its orphan drug Plenadren® to the biopharmaceutical company ViroPharma Incorporated. Plenadren® is a new treatment for adrenal insufficiency, also called Addison´s disease. The total potential deal value exceeds one billion SEK of which 220 million SEK will be paid by ViroPharma on closing.
Jul 22, 2011 09:20 EDT The Swedish specialty pharma company, DuoCort Pharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending marketing authorisation of its product Plenadren, a novel treatment for adrenal insufficiency.
Mar 15, 2011 01:30 EDT DuoCort’s new form of physiological treatment for the rare and life threatening disease adrenal insufficiency, also called Addison´s disease, was recently granted a registered Community Trademark within the EU. The trademark is PLENADREN. The product, which has orphan status in Europe and the USA, is currently in the European Union (EU) registration process for marketing authorisation.
Oct 27, 2009 07:11 EDT PULS's Head of Business Development, Maria Forss, is one of the 200 women selected by Maud Olofsson, the Minister for Enterprise and Energy, in collaboration with ALMI Företagspartner, to participate in the Styrelsekraft program. This is a national mentoring program targeting qualified and experienced women who have the ambition to be board members of both private and public companies.
Apr 14, 2010 05:38 EDT
DuoCort has developed an improved treatment for patients with adrenal insufficiency, a rare disease for which DuoCort has orphan drug designations in Europe and the USA. The new treatment is a dual release. This means it has an outer layer that immediately releases the drug and an inner core that releases the drug over the day to mimic the body´s own release of cortisol.
Length 2:48
